camptothecin has been researched along with Experimental Neoplasms in 153 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (9.80) | 18.7374 |
| 1990's | 25 (16.34) | 18.2507 |
| 2000's | 46 (30.07) | 29.6817 |
| 2010's | 60 (39.22) | 24.3611 |
| 2020's | 7 (4.58) | 2.80 |
| Authors | Studies |
|---|---|
| Adamovics, JA; Hutchinson, CR | 1 |
| Croom, D; Emerson, DL; Leitner, PP; Luzzio, MJ; McIntyre, G; Morton, B; Nanthakumar, SS; Profeta, S; Sisco, J; Uehling, DE | 1 |
| Ejima, A; Kawato, Y; Matsumoto, K; Mitsui, I; Ohsuki, S; Sato, K; Sugimori, M; Tagawa, H; Uoto, K; Yasuoka, M | 1 |
| Baguley, BC; Deady, LW; Denny, WA; Rodemann, T; Zhuang, L | 1 |
| Chang, LC; Goto, M; Hung, HY; Kuo, DH; Kuo, SC; Lee, KH; Liu, YQ; Morris-Natschke, SL; Nan, X; Pan, SL; Qian, K; Teng, CM; Wang, CY; Wang, MJ; Wu, TS; Wu, YC; Yang, JS; Yang, L; Yang, XM; Zhao, XB; Zhao, YL | 1 |
| Chen, W; Li, Z; Lu, C; Shen, Y; Zhang, M | 1 |
| Ben-David, G; Firer, MA; Gancz, A; Gellerman, G; Gilad, Y; Luboshits, G; Minnes, R; Senderowitz, H; Tuchinsky, H | 1 |
| Chen, NY; Mo, DL; Pan, CX; Su, GF; Wei, K; Wei, XW; Yuan, JM; Zhang, GH | 1 |
| Bi, K; Chen, S; Dong, G; Huang, Y; Li, Y; Sheng, C; Wu, S | 1 |
| Bist, G; Hwang, SY; Jang, H; Jeon, KH; Kadayat, TM; Kim, S; Kunwar, S; Kwon, Y; Lee, ES; Park, S; Seo, M; Sheen, N; Shrestha, A | 1 |
| Deng, J; Lei, F; Li, J; Liang, Z; Shi, T; Wang, Y; Wang, Z; Yang, X; Zhang, H | 1 |
| Bai, S; Cheng, Y; Kang, Y; Ma, X; Shao, J; Shi, X; Wang, Y; Xu, Z; Xue, P; Zhang, T | 1 |
| Brenner, AJ; Chiou, J; Gruslova, A; Pandey, R; Tiziani, S | 1 |
| Bai, S; Kang, Y; Lu, Y; Ma, X; Wang, Y; Wen, F; Xu, Z; Xue, P; Zhang, T; Zhang, X | 1 |
| Attiogbe, MKI; Cao, L; Cao, YX; Du, SS; Fan, S; Hei, YY; Lei, H; Li, GY; Liu, YJ; Yang, XY; Yao, JC; Zhang, GM; Zhang, H; Zhang, SQ; Zhang, XY | 1 |
| Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y | 1 |
| Chang, CH; Donahue, T; Jiang, J; Liao, YP; Lin, J; Lin, P; Liu, X; Meng, H; Nel, AE; Perrett, I; Wainberg, Z; Wu, N | 1 |
| Gong, N; Guo, HB; Guo, W; Liang, XJ; Wang, PC; Wang, YF; Wen, Y; Zhang, W | 1 |
| Doi, H; Inui, T; Kataoka, Y; Kida, T; Nakatsuji, M; Nishino, K; Sakamoto, S; Shimizu, S; Tamura, Y; Teraoka, Y | 1 |
| Artali, R; Bianchino, E; Cardile, F; Cincinelli, R; Colelli, F; Dallavalle, S; Guglielmi, M; Musso, L; Pisano, C | 1 |
| Chen, Y; Gou, M; Kang, T; Li, Y; Wu, Y; Zhu, J | 1 |
| Kaul, SC; Liu, M; Miyako, E; Nishikawa, M; Takahashi, J; Tei, T; Wadhawa, R; Yu, Y; Zhang, M | 1 |
| Chen, Q; Han, MK; Kang, Y; Merlin, D; Viennois, E; Wan, Y; Wang, L; Xiao, B; Zhang, Y; Zhang, Z | 1 |
| Bai, S; Gao, YE; Hou, M; Kang, Y; Ma, X; Shi, X; Xiao, B; Xu, Z; Xue, P; Zhang, T | 1 |
| Choi, HG; Gautam, M; Jin, SG; Kim, JO; Ku, SK; Nguyen, HT; Oh, KT; Ou, W; Soe, ZC; Thapa, RK; Yong, CS | 1 |
| Kang, Y; Ma, L; Xiao, B; Xie, D; Zhang, X; Zu, M | 1 |
| Bai, S; Jia, D; Kang, Y; Ma, X; Shao, J; Shi, X; Xu, Z; Xue, P; Zhang, X | 1 |
| Ahmad, E; Dai, Z; Gan, Y; Guo, S; He, S; Li, Y; Miao, Y; Shi, X; Song, W; Tian, F; Wang, R; Wu, Z; Yi, X; Yu, M; Zhang, X; Zhu, C | 1 |
| Akhtar, ML; Gan, Y; Han, F; Li, T; Li, Y; Liu, Z; Shi, J; Wang, T; Wang, Y | 1 |
| Del Bene, F; Germani, M; Magni, P; Terranova, N | 1 |
| Blackwood, E; Del Nagro, C; Evangelista, M; Jackson, PK; Kowanetz, K; Malek, S; O'Brien, T; Ramiscal, J; Xiao, Y | 1 |
| Bloomfield, A; Dorton, R; Guan, J; Leamon, CP; Nelson, M; Reddy, JA; Vetzel, M | 1 |
| Bhuniya, S; Hong, KS; Kim, EJ; Kim, JS; Lee, H; Maiti, S; Sessler, JL | 1 |
| Hao, X; Jie, J; Li, W; Tian, B; Yu, C; Zhang, X; Zhou, M | 1 |
| Chen, Q; Chen, S; Huang, C; Li, J; Liao, J; Liu, F; Su, G; Tang, W; Ye, Y | 1 |
| Hirano, S; Kuroda, A; Kuwatani, T; Kyogoku, N; Maki, T; Miyauchi, K; Shichinohe, T; Takeuchi, S; Tsuchikawa, T; Wada, M; Yamamura, Y | 1 |
| Chen, L; Ci, T; Ding, J; Yu, L | 1 |
| Eldon, MA; Hoch, U; Johnson, RK; Staschen, CM | 1 |
| Bhuniya, S; Cheong, C; Hong, KS; Kim, EJ; Kim, HM; Kim, JS; Lee, H; Maiti, S | 1 |
| Bouard, C; Boumendjel, A; Di Pietro, A; Gauthier, C; Gervot, H; Guitton, J; Honorat, M; Lecerf-Schmidt, F; Payen, L; Peres, B; Puisieux, A; Rioufol, C; Terreux, R | 1 |
| Choi, HG; Choi, JY; Kim, JH; Kim, JO; Ku, SK; Ramasamy, T; Ruttala, HB; Tran, TH; Yong, CS | 1 |
| Kang, Y; Liu, S; Wang, M; Xu, Z | 1 |
| Chen, Y; Lu, W; Ma, L; Wang, L; Xie, S | 1 |
| Matsui, H; Nagasaki, Y; Vong, LB; Yoshitomi, T | 1 |
| Chiang, YT; Lo, CL; Yen, YW | 1 |
| Chen, M; Li, X; Lu, J; Luo, X; Wei, J | 1 |
| Chen, X; Nan, X; Yu, C; Zhang, X; Zhou, M | 1 |
| Cheng, CJ; Deng, Y; Quijano, E; Saltzman, WM; Saucier-Sawyer, JK; Seo, YE; Zhang, J | 1 |
| Delalat, B; Donoghue, JF; Johns, TG; Kröger, N; McPhee, G; Pillay, V; Prestidge, CA; Rao, S; Rasi Ghaemi, S; Rogers, ML; Sheppard, VC; Voelcker, NH | 1 |
| Cano, F; Carcaboso, AM; Manzanares, A; Monterrubio, C; Mora, J; Pascual-Pasto, G; Schaiquevich, P; Sosnik, A; Tornero, JA; Vila-Ubach, M | 1 |
| Fan, ZC; Guo, N; Jiang, D; Teng, YO; Wang, LY; Wen, SP; Xiang, C; Yu, P; Zhang, YM; Zhao, HY; Zhou, Y | 1 |
| Bhuniya, S; Han, J; Hong, KS; Kim, EJ; Kim, HM; Kim, JS; Kumar, R; Lee, H; Shin, WS | 1 |
| Barnes, JC; Bruno, PM; Hemann, MT; Johnson, JA; Liao, L; Liu, J; Nguyen, HV | 1 |
| Li, S; Tian, H; Wu, J; Yao, D; Zhu, X | 1 |
| Hu, X; Hu, Y; Wu, B; Xing, D; Zhai, S | 1 |
| Choi, HG; Choi, JY; Din, FU; Kim, DS; Kim, DW; Kim, JO; Ku, SK; Mustapha, O; Oh, KT; Oh, YK; Thapa, RK; Yong, CS; Youn, YS | 1 |
| Adam, MJ; Anantha, M; Baker, JH; Bally, MB; Co, SJ; Dragowska, WH; Kozlowski, P; Kyle, AH; Lam, J; Minchinton, AI; Ng, SS; Oliver, T; Ramsay, E; Ruth, TJ; Sy, J; Yapp, DT; Yung, A | 1 |
| Antoniani, B; Biroccio, A; D'Incalci, M; Frapolli, R; Gilson, E; Leonetti, C; Mottolese, M; Riggio, G; Rizzo, A; Salvati, E; Scarsella, M; Staszewsky, L; Stevens, MF; Stoppacciaro, A; Zupi, G | 1 |
| Davis, ME | 1 |
| Askenasy, N; Fabian, I; Halperin, D; Reuveni, D; Shalit, I; Tsarfaty, G | 1 |
| Becherini, P; Cilli, M; Emionite, L; Greenberger, LM; Horak, ID; Loi, M; Pastorino, F; Ponzoni, M; Ribatti, D; Sapra, P | 1 |
| Kim, HJ; Kim, HS; Kim, SG; Kim, TG; Oh, ST; Park, HM; Park, JS; Sohn, HJ | 1 |
| Manabe, S; Matsumura, Y; Yasunaga, M | 1 |
| Hollis, CP; Li, T; Zhang, H; Zhang, Q | 1 |
| Azrak, RG; Bhattacharya, A; Cao, S; Durrani, FA; Rustum, YM; Toth, K | 1 |
| Furuta, T; Hashimoto, S; Kodaira, H; Kurita, A; Matsuzaki, T; Nohara, G; Sawada, S; Takagi, A; Ueno, S | 1 |
| Chen, J; Gu, Q; He, C; Huang, M; Xing, JZ | 1 |
| Granot, T; Meruelo, D | 1 |
| Chen, T; Li, Y; Wei, D; Xu, S; Zhang, H; Zhao, C; Zhao, T; Zhu, L | 1 |
| Ding, LY; Guo, M; Liu, YQ; Lu, Y; Ron, WT; Song, FF; Wang, Y; Yu, SQ | 1 |
| Cunin, F; Delalat, B; Dubljevic, V; Durand, JO; Johns, TG; Macardle, P; Moore, E; Rogers, ML; Secret, E; Smith, K; Voelcker, NH | 1 |
| Knežević, NŽ; Lin, VS | 1 |
| Cha, H; Cho, WJ; Lee, HY; Lee, JC; Lee, SJ; Lee, YH; Min, YJ; Moon, CH; Park, HJ; Park, JW; Seo, J; Song, HT | 1 |
| Kutner, A; Maciejewska, M; Milczarek, M; Psurski, M; Rosinska, S; Wietrzyk, J | 1 |
| Coudray, AM; De Gramont, A; Faivre, S; Gespach, C; Louvet, C; Raymond, E; Tournigand, C | 1 |
| Fang, HB; Houghton, PJ; Tan, M; Tian, GL | 3 |
| Boven, E; Erkelens, CA; Pinedo, HM; Schlüper, HM; Tohgo, A; van Hattum, AH | 1 |
| Boven, E; Hoogsteen, IJ; Kohlhagen, G; Maliepaard, M; Pinedo, HM; Pommier, Y; Scheffer, GL; Scheper, RJ; Schlüper, HM; van Hattum, AH | 1 |
| Chen, SF; Hollister, B; Mishra, A; Sands, H; Stoeckler, JD | 1 |
| Chen, HZ; Chen, Y; Ding, XQ; Kong, QY; Wang, AX | 1 |
| Carenini, N; Carminati, P; Cucco, C; De Cesare, M; Merlini, L; Penco, S; Perego, P; Pisano, C; Pratesi, G; Righetti, SC; Vesci, L; Zunino, F | 1 |
| Chen, LM; Ding, Y; Fu, LW; Liang, YJ; Pan, QC; Xiong, HY; Yang, XP | 1 |
| Chai, LP; Su, ZZ; Xian, ZX | 1 |
| De Cesare, M; Giordano, V; Laccabue, D; Lanzi, C; Marcellini, M; Petrangolini, G; Pisano, C; Pratesi, G; Supino, R; Zunino, F | 1 |
| Ahmad, I; Ali, S; Ma, L; Parmar, M; Ugwu, S; Xuan, T; Zhang, JA | 1 |
| Blackman, RK; Bulawa, CE; Charlton, P; Connolly, K; Fleming, JA; McClendon, AK; Osheroff, N; Reimer, C; Rudolph-Owen, LA; Sappal, DS; Thoroddsen, V | 1 |
| Kumazawa, E; Ochi, Y | 1 |
| Sasako, M; Ushijima, T | 1 |
| Barbarino, M; Bucci, F; Bufali, S; Carminati, P; Luisi, PL; Pisano, C; Santaniello, M; Stano, P | 1 |
| Bergottini, R; De Cesare, M; Pratesi, G; Veneroni, S; Zunino, F | 1 |
| Chen, LB; Dai, M; Owen, DA; Tai, IT | 1 |
| Hoffman, RM | 1 |
| Mai, M; Takahashi, Y; Yasumoto, K | 1 |
| Bucana, CD; Carter, KB; Jasser, SA; Kim, S; Myers, JN; Wang, Z; Yazici, YD | 1 |
| Boltze, C; Fahlke, J; Hribaschek, A; Kuhn, R; Lippert, H; Meyer, F; Pross, M; Ridwelski, K | 1 |
| Camuso, A; Castaneda, S; Fager, K; Flefleh, C; Inigo, I; Kan, D; Luo, FR; McGlinchey, K; Rose, WC; Wild, R | 1 |
| Chandna, P; Khandare, JJ; Minko, T; Pozharov, VP; Wang, Y | 1 |
| Hata, K; Koyanagi, S; Kuramoto, Y; Ohdo, S; Shimeno, H; Soeda, S | 1 |
| Belfiore, P; Croce, AC; Dal Bo, L; Farina, C; Misiano, P; Petrangolini, G; Pratesi, G; Supino, R; Tortoreto, M; Zunino, F | 1 |
| Coy, DH; Fuselier, JA; Gonzales, N; Jensen, RT; Mackey, LV; Mantey, SA; Moody, TW; Pradhan, T; Sun, LC | 1 |
| Benedetti, V; Beretta, GL; Carminati, P; Dallavalle, S; De Cesare, M; Merlini, L; Penco, S; Pisano, C; Pratesi, G; Tinelli, S; Zunino, F | 1 |
| Cao, S; Creaven, PJ; Durrani, FA; Iyer, RV; Javle, MM; Lawrence, DD; Noel, DC; Pendyala, L; Rustum, YM; Smith, PF | 1 |
| Dubois, RN; Hatakeyama, N; Horikawa, Y; Jin, M; Komatsu, K; Matsuhashi, T; Odashima, M; Ohba, R; Otaka, M; Oyake, J; Wada, I; Watanabe, S | 1 |
| Anantha, M; Bally, MB; Meijs, M; Ramsay, EC; Strutt, D; Waterhouse, D; Webb, MS; Zastre, J; Zonderhuis, J | 1 |
| Baracos, VE; Dieleman, LA; Field, CJ; Murray, D; Sawyer, MB; Xue, H | 1 |
| Arranz, V; Boukaissi, M; Chéné, AS; de Coupade, C; Dubois, V; Fruchart, JS; Kearsey, J; Meyer-Losic, F; Michel, M; Nicolazzi, C; Quinonero, J; Ravel, D; Ribes, F; Tranchant, I; Zoubaa, I | 1 |
| Greene, LA; McGuire, JC | 1 |
| Cheshire, PJ; Danks, MK; Friedman, HS; Hallman, JD; Houghton, JA; Houghton, PJ; Lutz, L | 1 |
| Wall, ME; Wani, MC | 1 |
| Armand, JP | 1 |
| Andoh, T; Ishida, R | 1 |
| Potmesil, M | 1 |
| Johnson, RK; McCabe, FL | 1 |
| Aboud, M; Aflalo, E; Benharroch, D; Chechelnitsky, G; Priel, E; Segal, S | 1 |
| André, S; Bissery, MC; Lavelle, F; Riou, JF; Roquet, F | 1 |
| Bissery, MC; Chabot, GG; Lavelle, F; Vrignaud, P | 1 |
| Fukuoka, M; Kudoh, S; Masuda, N | 1 |
| Giovanella, BC; Harris, N; Natelson, E; Stehlin, JS; Vardeman, D | 1 |
| Danks, MK; Houghton, JA; Houghton, PJ; Luo, X; Stewart, CF; Thompson, J; Zamboni, WC | 1 |
| Bugat, R; Canal, P; Cussac, D; Guichard, S; Hennebelle, I | 1 |
| Aoyagi, K; Aoyagi, Y; Asao, T; Okazaki, S; Sano, M; Utsugi, T; Wierzba, K; Yamada, Y | 1 |
| Saijo, N | 1 |
| Houghton, PJ; Stewart, CF; Thompson, J | 1 |
| Canal, P; Chabot, GG; Lokiec, F; Robert, J | 1 |
| Baldwin, AS; Cusack, JC; Liu, R; Wang, CY | 1 |
| Cheshire, PJ; Danks, MK; Houghton, PJ; Krull, EJ; Morton, CL; Naeve, CW; Pawlik, CA; Potter, PM; Richmond, LB | 1 |
| Bastow, KF; Chang, JY; Chen, HX; Cheng, YC; Fu, Q; Guan, J; Guo, X; Jiang, Z; Lee, KH; Wang, HK; Zhu, XK | 1 |
| Conover, CD; Greenwald, RB; Pendri, A; Shum, KL | 1 |
| Gilbert, B; Giovanella, BC; Kleinerman, E; Knight, V; Koshkina, N; Waldrep, C | 1 |
| Boushey, RP; Drucker, DJ; Yusta, B | 1 |
| Harada, M; Murata, J; Okuno, S; Sakakibara, H; Sakamura, Y; Suzuki, T | 1 |
| Giovanella, BC; Harris, NJ; Hinz, HR; Kozielski, AJ; Stehlin, JS; Vardeman, DM | 1 |
| Densmore, CL; Gautam, A; Gilbert, B; Knight, V; Koshkina, N; Melton, S; Roberts, L; Waldrep, JC | 1 |
| Agrawal, S; Ball, R; Chen, SF; Dexter, DL; Hollister, BA; Kandimalla, ER; Lombardi, G; Lucas, T; Yu, D | 1 |
| Agrawal, S; Hang, J; Kandimalla, ER; Li, M; Shi, Z; Wang, H; Yu, D; Zhang, R | 1 |
| Cotezee, ML; Klein, K; Ove, P; Sartiano, GP | 1 |
| Coetzee, ML; Klein, K; Ove, P; Sartiano, GP | 1 |
| Adamson, RH; Mead, JA; Sieber, SM | 1 |
| Hirabayashi, N; Jinushi, K; Kim, R; Nishiyama, M; Okada, K; Toge, T | 1 |
| Taguchi, T | 1 |
| Furuta, T; Yokokura, T | 1 |
| Matsushita, M; Matsuzaki, T; Saito, H; Tsuruo, T; Yokokura, T | 1 |
| Baba, H; Kunimoto, T; Miyasaka, T; Mutai, M; Nitta, K; Sawada, S; Takeuchi, M; Tanaka, T; Uehara, N; Yokokura, T | 3 |
| Kline, I | 1 |
| Brockman, RW | 1 |
| Becker, JE; Bushnell, DE; Potter, VR | 1 |
| Schultz, AG | 1 |
| Bhuyan, BK; Fraser, TJ; Li, LH; Olin, EJ | 1 |
| Bhuyan, BK; Fraser, TJ; Gray, LG; Kuentzel, SL; Neil, GL | 1 |
16 review(s) available for camptothecin and Experimental Neoplasms
| Article | Year |
|---|---|
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Cyclodextrins; Delayed-Action Preparations; Drug Design; Half-Life; Humans; Nanoparticles; Neoplasms; Neoplasms, Experimental | 2009 |
Focus on gastric cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cadherins; Camptothecin; Carcinogens; Docetaxel; Fluorouracil; Gerbillinae; Herpesvirus 4, Human; Humans; Irinotecan; Lymphatic Metastasis; Mice; Mice, Transgenic; Models, Animal; Mutation; Neoplasm Staging; Neoplasms, Experimental; Rats; Stomach Neoplasms; Taxoids | 2004 |
Camptothecin and taxol: discovery to clinic--thirteenth Bruce F. Cain Memorial Award Lecture.
Topics: Animals; Awards and Prizes; Camptothecin; Chemistry, Physical; Clinical Trials as Topic; Drug Screening Assays, Antitumor; History, 20th Century; Humans; Medical Oncology; Neoplasms; Neoplasms, Experimental; Paclitaxel; Societies, Medical; United States | 1995 |
[Recent progress in the study of the mechanism of resistance to DNA topoisomerase inhibitors].
Topics: Animals; Antineoplastic Agents; Camptothecin; Drug Resistance; Humans; Neoplasms, Experimental; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1994 |
Camptothecins: from bench research to hospital wards.
Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Neoplasms; Neoplasms, Experimental | 1994 |
Preclinical evaluation of CPT-11 and its active metabolite SN-38.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; DNA Damage; Drug Resistance; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms, Experimental; Topoisomerase I Inhibitors | 1996 |
Irinotecan (CPT-11): pharmacology and clinical applications.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Humans; Irinotecan; Neoplasms; Neoplasms, Experimental | 1996 |
Protocols for the treatment of human tumor xenografts with camptothecins.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Protocols; Disease Models, Animal; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Rats; Transplantation, Heterologous | 1996 |
New chemotherapeutic agents for the treatment of non-small cell lung cancer: the Japanese experience.
Topics: Alkaloids; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbazoles; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Glucosides; Humans; Irinotecan; Japan; Lung Neoplasms; Mitomycin; Mitomycins; Neoplasms, Experimental; Paclitaxel; Purine Nucleosides; Staurosporine; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1998 |
Animal models for studying the action of topoisomerase I targeted drugs.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Division; Disease Models, Animal; Enzyme Inhibitors; Humans; Molecular Structure; Neoplasms, Experimental; Rodentia; Topoisomerase I Inhibitors; Transplantation, Heterologous | 1998 |
[Irinotecan pharmacokinetics].
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Biotransformation; Blood Proteins; Body Fluid Compartments; Camptothecin; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Half-Life; Humans; Inactivation, Metabolic; Irinotecan; Liver; Mice; Models, Biological; Neoplasm Proteins; Neoplasms; Neoplasms, Experimental; Prodrugs; Rats; Tissue Distribution; Topoisomerase I Inhibitors | 1998 |
Pharmacology of antitumor agents from higher plants.
Topics: Animals; Antineoplastic Agents, Phytogenic; Aporphines; Camptothecin; Carcinoma, Squamous Cell; Chemical Phenomena; Chemistry; Etoposide; Humans; Leukemia L1210; Leukemia, Experimental; Leukemia, Lymphoid; Maytansine; Melanoma; Naphthoquinones; Nasopharyngeal Neoplasms; Neoplasms; Neoplasms, Experimental; Phenanthrenes; Structure-Activity Relationship; Teniposide; Vinblastine; Vincristine | 1976 |
[DNA topoisomerase inhibitor as chemotherapeutic drug--clinical point of view].
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Dogs; Drug Evaluation; Female; Genital Neoplasms, Female; Humans; Irinotecan; Leukocyte Count; Lung Neoplasms; Mice; Neoplasms, Experimental; Topoisomerase I Inhibitors | 1991 |
Biochemical aspects of drug combinations.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Bleomycin; Camptothecin; Cell Division; Cytarabine; Deferoxamine; Diamines; DNA, Neoplasm; Doxorubicin; Drug Therapy, Combination; Leukemia L1210; Macromolecular Substances; Mice; Neoplasms; Neoplasms, Experimental; Nitrosourea Compounds; Purine Nucleotides; Ribonucleotide Reductases; Thioguanine; Triazoles | 1974 |
Camptothecin.
Topics: Animals; Camptothecin; Chemical Phenomena; Chemistry; Culture Techniques; Cyclization; DNA, Neoplasm; Esters; Humans; Lactams; Mice; Models, Chemical; Neoplasms, Experimental; Pyridones; RNA, Neoplasm | 1973 |
2 trial(s) available for camptothecin and Experimental Neoplasms
| Article | Year |
|---|---|
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colorectal Neoplasms; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fluorouracil; Glucuronates; Humans; Intestinal Mucosa; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Mucositis; Neoplasm Transplantation; Neoplasms, Experimental; Pyrazoles; Rats; Rats, Inbred F344; Sulfonamides | 2007 |
136 other study(ies) available for camptothecin and Experimental Neoplasms
| Article | Year |
|---|---|
Prodrug analogues of the antitumor alkaloid camptothecin.
Topics: Animals; Antineoplastic Agents; Camptothecin; Leukemia L1210; Leukemia, Experimental; Lung Neoplasms; Melanoma; Mice; Neoplasms, Experimental | 1979 |
Synthesis, topoisomerase I inhibitory activity, and in vivo evaluation of 11-azacamptothecin analogs.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Survival; Cells, Cultured; Female; In Vitro Techniques; Magnetic Resonance Spectroscopy; Mice; Mice, Nude; Neoplasms, Experimental; Solubility; Structure-Activity Relationship; Topoisomerase I Inhibitors | 1995 |
Antitumor agents. 7. Synthesis and antitumor activity of novel hexacyclic camptothecin analogues.
Topics: Animals; Antineoplastic Agents; Camptothecin; Drug Screening Assays, Antitumor; Leukemia P388; Mice; Neoplasms, Experimental; Polycyclic Compounds; Structure-Activity Relationship; Tumor Cells, Cultured | 1994 |
Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines.
Topics: Animals; Antineoplastic Agents; Cell Division; Drug Screening Assays, Antitumor; Humans; Mice; Naphthyridines; Neoplasm Transplantation; Neoplasms, Experimental; Structure-Activity Relationship; Transplantation, Heterologous; Tumor Cells, Cultured | 2003 |
Design, synthesis, mechanisms of action, and toxicity of novel 20(s)-sulfonylamidine derivatives of camptothecin as potent antitumor agents.
Topics: Amidines; Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Female; HCT116 Cells; Humans; KB Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Conformation; Neoplasms, Experimental; Structure-Activity Relationship; Sulfonamides; Topoisomerase I Inhibitors | 2014 |
Design and synthesis of 2-phenylnaphthalenoids as inhibitors of DNA topoisomeraseIIα and antitumor agents.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Proliferation; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; HeLa Cells; Humans; Mice; Mice, Nude; Molecular Structure; Naphthalenes; Neoplasms, Experimental; Quantitative Structure-Activity Relationship; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2014 |
Discovery of potent molecular chimera (CM358) to treat human metastatic melanoma.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Heterocyclic Compounds, 3-Ring; Humans; Melanoma; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Neoplasms, Experimental; Pyrimidinones; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2017 |
Cryptolepine and aromathecin based mimics as potent G-quadruplex-binding, DNA-cleavage and anticancer agents: Design, synthesis and DNA targeting-induced apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Binding Sites; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Breaks, Double-Stranded; DNA Cleavage; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; G-Quadruplexes; Heterocyclic Compounds, 4 or More Rings; Humans; Indole Alkaloids; Mice; Molecular Structure; Neoplasms, Experimental; Quinolines; Structure-Activity Relationship | 2019 |
Water-soluble derivatives of evodiamine: Discovery of evodiamine-10-phosphate as an orally active antitumor lead compound.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Female; HCT116 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Phosphates; Quinazolines; Solubility; Structure-Activity Relationship; Water | 2021 |
Identification of new halogen-containing 2,4-diphenyl indenopyridin-5-one derivative as a boosting agent for the anticancer responses of clinically available topoisomerase inhibitors.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Halogens; Humans; Indenes; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Poly-ADP-Ribose Binding Proteins; Pyridones; Structure-Activity Relationship; Topoisomerase Inhibitors; Tumor Cells, Cultured | 2022 |
Design, synthesis and bioactivity evaluation of novel evodiamine derivatives with excellent potency against gastric cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Quinazolines; Stomach Neoplasms; Structure-Activity Relationship | 2022 |
Smart Unimolecular Micelle-Based Polyprodrug with Dual-Redox Stimuli Response for Tumor Microenvironment: Enhanced in Vivo Delivery Efficiency and Tumor Penetration.
Topics: Animals; Camptothecin; Delayed-Action Preparations; Female; HeLa Cells; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Neoplasms, Experimental; Oxidation-Reduction; Prodrugs; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2019 |
Stable Isotope Dilution LC-HRMS Assay To Determine Free SN-38, Total SN-38, and SN-38G in a Tumor Xenograft Model after Intravenous Administration of Antibody-Drug Conjugate (Sacituzumab Govitecan).
Topics: Administration, Intravenous; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Chromatography, High Pressure Liquid; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Immunoconjugates; Indicator Dilution Techniques; Irinotecan; Mass Spectrometry; Mice; Mice, SCID; Molecular Structure; Neoplasms, Experimental | 2020 |
Reactive oxygen species-activatable camptothecin polyprodrug based dextran enhances chemotherapy efficacy by damaging mitochondria.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Proliferation; Dextrans; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Inbred Strains; Mitochondria; Molecular Structure; Nanomedicine; Neoplasms, Experimental; Particle Size; Prodrugs; Reactive Oxygen Species; Surface Properties; Tumor Cells, Cultured; Tumor Microenvironment | 2020 |
F10, a new camptothecin derivative, was identified as a new orally-bioavailable, potent antitumor agent.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Biological Availability; Camptothecin; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Structure-Activity Relationship; Tumor Cells, Cultured | 2020 |
Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Pancreatic Ductal; Humans; Irinotecan; Mice; Nanoparticles; Neoplasm Metastasis; Neoplasms, Experimental; Oligopeptides; Silicon Dioxide; Transcytosis; Xenograft Model Antitumor Assays | 2017 |
Carrier-free, self-assembled pure drug nanorods composed of 10-hydroxycamptothecin and chlorin e6 for combinatorial chemo-photodynamic antitumor therapy in vivo.
Topics: A549 Cells; Animals; Camptothecin; Cell Line, Tumor; Chlorophyllides; Female; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Nanotubes; Neoplasms, Experimental; Photochemotherapy; Porphyrins; Radiation-Sensitizing Agents; Xenograft Model Antitumor Assays | 2017 |
Solubility-Improved 10-O-Substituted SN-38 Derivatives with Antitumor Activity.
Topics: Animals; Antineoplastic Agents; Camptothecin; Humans; Irinotecan; Male; Mice; Molecular Structure; Neoplasms, Experimental; Prostatic Neoplasms; Structure-Activity Relationship | 2017 |
Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Proliferation; Cells, Cultured; Disulfides; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Neoplasms, Experimental; Structure-Activity Relationship; Topoisomerase I Inhibitors; Tyrosine | 2018 |
Carbonate esters turn camptothecin-unsaturated fatty acid prodrugs into nanomedicines for cancer therapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carbonates; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Esters; Fatty Acids, Unsaturated; Humans; Hydrophobic and Hydrophilic Interactions; Injections, Subcutaneous; Mice; Mice, Inbred C57BL; Molecular Structure; Nanomedicine; Neoplasms, Experimental; Particle Size; Prodrugs; Structure-Activity Relationship; Surface Properties | 2018 |
Self-assembled nanodiamond supraparticles for anticancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Caprylates; Cell Membrane Permeability; Drug Carriers; Female; Fibroblasts; Fluorocarbons; HeLa Cells; HT29 Cells; Humans; Mice, Inbred BALB C; Nanodiamonds; Nanomedicine; Neoplasms, Experimental; Phospholipids; Polyethylene Glycols | 2018 |
Silencing of Intestinal Glycoprotein CD98 by Orally Targeted Nanoparticles Enhances Chemosensitization of Colon Cancer.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Proliferation; Colonic Neoplasms; Disease Models, Animal; Drug Delivery Systems; Drug Screening Assays, Antitumor; Female; Fusion Regulatory Protein-1; Humans; Intestines; Mice; Mice, Inbred C57BL; Nanoparticles; Neoplasms, Experimental; RNA, Small Interfering | 2018 |
Irinotecan delivery by unimolecular micelles composed of reduction-responsive star-like polymeric prodrug with high drug loading for enhanced cancer therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Biocompatible Materials; Camptothecin; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Screening Assays, Antitumor; HeLa Cells; Humans; Injections, Intravenous; Irinotecan; MCF-7 Cells; Mice; Micelles; Molecular Structure; Neoplasms, Experimental; Oxidation-Reduction; Particle Size; Polymers; Prodrugs; Structure-Activity Relationship; Surface Properties | 2018 |
Folate receptor-mediated celastrol and irinotecan combination delivery using liposomes for effective chemotherapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Cycle; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Carriers; Drug Screening Assays, Antitumor; Folate Receptors, GPI-Anchored; Humans; Irinotecan; Liposomes; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Pentacyclic Triterpenes; Structure-Activity Relationship; Triterpenes; Tumor Cells, Cultured | 2018 |
Chondroitin sulfate-functionalized polymeric nanoparticles for colon cancer-targeted chemotherapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Proliferation; Cell Survival; Chondroitin Sulfates; Colonic Neoplasms; Drug Delivery Systems; Drug Screening Assays, Antitumor; Humans; Hydrodynamics; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms, Experimental; Particle Size; Polylactic Acid-Polyglycolic Acid Copolymer; Surface Properties; Tumor Cells, Cultured | 2019 |
Enhanced Tumor Penetration and Chemotherapy Efficiency by Covalent Self-Assembled Nanomicelle Responsive to Tumor Microenvironment.
Topics: Animals; Camptothecin; Delayed-Action Preparations; HeLa Cells; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Nanostructures; Neoplasms, Experimental; Prodrugs; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2019 |
Chain-Length- and Saturation-Tuned Mechanics of Fluid Nanovesicles Direct Tumor Delivery.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Proliferation; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Screening Assays, Antitumor; Humans; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Molecular; Nanoparticles; Neoplasms, Experimental; Optical Imaging; Pancreatic Neoplasms; Particle Size; Stress, Mechanical; Surface Properties; Tumor Cells, Cultured | 2019 |
A cascade-reaction enabled synergistic cancer starvation/ROS-mediated/chemo-therapy with an enzyme modified Fe-based MOF.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biocatalysis; Camptothecin; Cell Proliferation; Chlorides; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Ferric Compounds; Glucose Oxidase; HeLa Cells; Humans; Hydrogen Peroxide; Metal-Organic Frameworks; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Particle Size; Reactive Oxygen Species; Structure-Activity Relationship; Tumor Cells, Cultured | 2019 |
A predictive pharmacokinetic-pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combination.
Topics: Algorithms; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Cell Line, Tumor; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kinetics; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Neoplasm Transplantation; Neoplasms, Experimental; Xenograft Model Antitumor Assays | 2013 |
Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbolines; Cell Cycle Checkpoints; Checkpoint Kinase 1; Dacarbazine; Deoxycytidine; DNA Damage; Gemcitabine; HCT116 Cells; High-Throughput Nucleotide Sequencing; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms; Neoplasms, Experimental; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Temozolomide; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2013 |
Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Folic Acid; HeLa Cells; Humans; Irinotecan; Mice, Inbred BALB C; Mice, Inbred DBA; Mice, Nude; Neoplasms; Neoplasms, Experimental; Paclitaxel; Taxoids; Topotecan; Treatment Outcome; Vinca Alkaloids; Xenograft Model Antitumor Assays | 2014 |
An activatable theranostic for targeted cancer therapy and imaging.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Survival; Diagnostic Imaging; Drug Delivery Systems; Fluorescent Dyes; Humans; Irinotecan; Mice; Molecular Imaging; Neoplasms, Experimental; Prodrugs; Sulfhydryl Compounds; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Functional core/shell drug nanoparticles for highly effective synergistic cancer therapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Female; Gold; Laser Therapy; Materials Testing; Metal Nanoparticles; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Tissue Distribution; Xenograft Model Antitumor Assays | 2014 |
Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Movement; Colorectal Neoplasms; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Irinotecan; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; NF-kappaB-Inducing Kinase; Oligopeptides; Protein Serine-Threonine Kinases; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
The key role of calreticulin in immunomodulation induced by chemotherapeutic agents.
Topics: Animals; Antigens, Surface; Antineoplastic Agents; Apoptosis; Calreticulin; Camptothecin; Carcinoma, Lewis Lung; CD3 Complex; Cell Line, Tumor; Cell Survival; Cisplatin; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Histocompatibility Antigens Class I; Humans; Immunomodulation; Lymphocyte Count; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mitomycin; Mitoxantrone; Neoplasm Transplantation; Neoplasms, Experimental; Protein Transport; T-Lymphocytes; Tumor Microenvironment | 2015 |
Tumor regression achieved by encapsulating a moderately soluble drug into a polymeric thermogel.
Topics: Animals; Camptothecin; Cell Line, Tumor; Diffusion; Hydrogels; Irinotecan; Mice; Mice, Nude; Nanocapsules; Neoplasms, Experimental; Particle Size; Polyesters; Polyethylene Glycols; Rabbits; Remission Induction; Solubility; Treatment Outcome | 2014 |
Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models.
Topics: Animals; Antineoplastic Agents; Camptothecin; Dogs; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Irinotecan; Male; Mice; Mice, Nude; Mice, SCID; Neoplasms, Experimental; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Species Specificity; Topoisomerase I Inhibitors; Treatment Outcome; Xenograft Model Antitumor Assays | 2014 |
An activatable prodrug for the treatment of metastatic tumors.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; HeLa Cells; Humans; Hydrogen Peroxide; Irinotecan; Lung Neoplasms; Mice; Molecular Structure; Neoplasms, Experimental; Prodrugs; Structure-Activity Relationship; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
MBL-II-141, a chromone derivative, enhances irinotecan (CPT-11) anticancer efficiency in ABCG2-positive xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Chromatography, High Pressure Liquid; Chromones; HEK293 Cells; Humans; Indoles; Irinotecan; Mass Spectrometry; Mice; Neoplasm Proteins; Neoplasms, Experimental; Transfection; Xenograft Model Antitumor Assays | 2014 |
Engineering of a lipid-polymer nanoarchitectural platform for highly effective combination therapy of doxorubicin and irinotecan.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line; Cell Proliferation; Doxorubicin; Drug Combinations; HeLa Cells; Humans; Irinotecan; Lecithins; Lipid Bilayers; MCF-7 Cells; Mice; Mice, Nude; Nanoparticles; Neoplasms, Experimental; Polymers; Structure-Activity Relationship | 2015 |
Glutathione- and pH-responsive nonporous silica prodrug nanoparticles for controlled release and cancer therapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Survival; Delayed-Action Preparations; Diffusion; Doxorubicin; Glutathione; HeLa Cells; Humans; Hydrogen-Ion Concentration; Nanocapsules; Neoplasms, Experimental; Porosity; Prodrugs; Silicon Dioxide | 2015 |
Design, synthesis and biological evaluation of novel homocamptothecin analogues as potent antitumor agents.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; HT29 Cells; Humans; Mice; Molecular Structure; Neoplasms, Experimental; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2015 |
Development of an oral nanotherapeutics using redox nanoparticles for treatment of colitis-associated colon cancer.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Azoxymethane; Camptothecin; Cell Line, Tumor; Colitis; Colonic Neoplasms; Dextrans; Drug Delivery Systems; Drug Screening Assays, Antitumor; Endoscopy; Free Radical Scavengers; Inflammation; Irinotecan; Male; Mice; Mice, Inbred ICR; Nanomedicine; Nanoparticles; Neoplasms, Experimental; Nitrogen Oxides; Oxidation-Reduction; Reactive Oxygen Species; Sulfates | 2015 |
Reactive oxygen species and glutathione dual redox-responsive micelles for selective cytotoxicity of cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Diffusion; Glutathione; Humans; Materials Testing; Mice; Mice, Nude; Micelles; Nanocapsules; Neoplasms, Experimental; Oxidation-Reduction; Reactive Oxygen Species; Treatment Outcome | 2015 |
Spatial distribution and antitumor activities after intratumoral injection of fragmented fibers with loaded hydroxycamptothecin.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Delayed-Action Preparations; Diffusion; Female; Hep G2 Cells; Humans; Injections, Intralesional; Mice; Nanocapsules; Nanofibers; Neoplasms, Experimental; Particle Size; Survival Rate; Tissue Distribution; Treatment Outcome | 2015 |
Shape regulated anticancer activities and systematic toxicities of drug nanocrystals in vivo.
Topics: Animals; Camptothecin; Cell Line, Tumor; Cell Survival; Crystallization; Drug Compounding; Female; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms, Experimental; Particle Size; Treatment Outcome | 2016 |
Systemic delivery of blood-brain barrier-targeted polymeric nanoparticles enhances delivery to brain tissue.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Transport; Blood-Brain Barrier; Brain; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Delayed-Action Preparations; Drug Carriers; Drug Delivery Systems; Glioma; Humans; Injections, Intravenous; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms, Experimental; Polymers; Tissue Distribution | 2015 |
Targeted drug delivery using genetically engineered diatom biosilica.
Topics: Animals; Antibodies; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cloning, Molecular; Diatoms; Drug Delivery Systems; Gene Expression Regulation; Genetic Engineering; Immunoglobulin G; Liposomes; Lymphoma, B-Cell; Mice; Micelles; Nanoparticles; Neoplasms, Experimental; Neuroblastoma; Particle Size; Recombinant Fusion Proteins; Silicon Dioxide; Transplantation, Heterologous | 2015 |
SN-38-loaded nanofiber matrices for local control of pediatric solid tumors after subtotal resection surgery.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Child, Preschool; Diffusion; Female; Humans; Irinotecan; Male; Mice; Nanocapsules; Nanofibers; Neoplasm Recurrence, Local; Neoplasms, Experimental; Particle Size; Postoperative Care; Tissue Distribution; Treatment Outcome | 2016 |
Low toxic and high soluble camptothecin derivative 2-47 effectively induces apoptosis of tumor cells in vitro.
Topics: Apoptosis; Camptothecin; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Design; Humans; Neoplasms, Experimental; Solubility; Treatment Outcome | 2016 |
Hypoxia-directed and activated theranostic agent: Imaging and treatment of solid tumor.
Topics: A549 Cells; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Proliferation; Fluorescent Dyes; HeLa Cells; Humans; Irinotecan; Neoplasms, Experimental; Oxygen; Theranostic Nanomedicine; Treatment Outcome; Tumor Hypoxia | 2016 |
Using an RNAi Signature Assay To Guide the Design of Three-Drug-Conjugated Nanoparticles with Validated Mechanisms, In Vivo Efficacy, and Low Toxicity.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma; Cell Line, Tumor; Doxorubicin; Drug Delivery Systems; Mice; Molecular Structure; Nanoparticles; Neoplasms, Experimental; Organoplatinum Compounds; Oxaliplatin; Prodrugs; RNA Interference | 2016 |
Tumor-cell targeting polydiacetylene micelles encapsulated with an antitumor drug for the treatment of ovarian cancer.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Death; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Lysosomes; Mice; Micelles; Molecular Structure; Neoplasms, Experimental; Ovarian Neoplasms; Polyacetylene Polymer; Polymers; Polyynes; Structure-Activity Relationship | 2017 |
Visible light-induced crosslinking and physiological stabilization of diselenide-rich nanoparticles for redox-responsive drug release and combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Survival; Cross-Linking Reagents; Delayed-Action Preparations; Doxorubicin; Drug Stability; Humans; Light; MCF-7 Cells; Nanocapsules; Neoplasms, Experimental; Oxidation-Reduction; Selenium Compounds; Treatment Outcome | 2017 |
Irinotecan-loaded double-reversible thermogel with improved antitumor efficacy without initial burst effect and toxicity for intramuscular administration.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Hydrogels; Injections, Intramuscular; Irinotecan; Lipids; Mice; Mice, Nude; Nanoparticles; Neoplasms, Experimental | 2017 |
Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Hypoxia; Doxorubicin; Fluorouracil; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; Irinotecan; Liposomes; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Mice; Nanocapsules; Neoplasms, Experimental; Neovascularization, Pathologic; Tissue Distribution; Xenograft Model Antitumor Assays | 2008 |
G-quadruplex ligand RHPS4 potentiates the antitumor activity of camptothecins in preclinical models of solid tumors.
Topics: Acridines; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Synergism; Female; G-Quadruplexes; Humans; Immunohistochemistry; Ligands; Male; Mice; Mice, Nude; Neoplasms, Experimental; Xenograft Model Antitumor Assays | 2008 |
Moxifloxacin increases anti-tumor and anti-angiogenic activity of irinotecan in human xenograft tumors.
Topics: Angiogenesis Inhibitors; Animals; Anti-Infective Agents; Antineoplastic Agents; Aza Compounds; Camptothecin; Cell Proliferation; Drug Synergism; Female; Fluoroquinolones; Humans; Interleukin-8; Irinotecan; Mice; Mice, SCID; Moxifloxacin; Neoplasms, Experimental; Platelet Endothelial Cell Adhesion Molecule-1; Quinolines; Ultrasonography, Doppler; Xenograft Model Antitumor Assays | 2010 |
Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Female; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms, Experimental; Neovascularization, Pathologic; Neuroblastoma; Polyethylene Glycols; Survival Rate; Topoisomerase I Inhibitors | 2010 |
Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines; Carcinoembryonic Antigen; Colorectal Neoplasms; Dendritic Cells; Female; Fluorouracil; Leucovorin; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory | 2010 |
New concept of cytotoxic immunoconjugate therapy targeting cancer-induced fibrin clots.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Drug Design; Female; Fibrin; Immunotoxins; Irinotecan; Mice; Neoplasms, Experimental | 2011 |
Preparation and antitumor study of camptothecin nanocrystals.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Compounding; Drug Stability; Drug Storage; Female; Humans; Mice; Mice, Inbred BALB C; Microscopy, Electron, Scanning; Nanoparticles; Neoplasms, Experimental; Particle Size; Solubility; Sonication; Surface Properties; Xenograft Model Antitumor Assays | 2011 |
Augmented therapeutic efficacy of irinotecan is associated with enhanced drug accumulation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Chromatography, High Pressure Liquid; Cysteine; Drug Synergism; Female; Humans; Immunohistochemistry; Irinotecan; Mice; Mice, Nude; Neoplasms, Experimental; Organoselenium Compounds; Selenocysteine; Xenograft Model Antitumor Assays | 2011 |
Antitumor activity of IHL-305, a novel pegylated liposome containing irinotecan, in human xenograft models.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Humans; Irinotecan; Liposomes; Male; Mice; Mice, Nude; Neoplasms, Experimental; Polyethylene Glycols; Xenograft Model Antitumor Assays | 2012 |
SN-38 loaded polymeric micelles to enhance cancer therapy.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Survival; Diffusion; Humans; Irinotecan; Micelles; Nanocapsules; Neoplasms, Experimental; Tumor Cells, Cultured | 2012 |
The role of natural killer cells in combinatorial anti-cancer therapy using Sindbis viral vectors and irinotecan.
Topics: Animals; Camptothecin; Female; Humans; Irinotecan; Killer Cells, Natural; Mice; Mice, SCID; Neoplasms, Experimental; Oncolytic Virotherapy; Oncolytic Viruses; Ovarian Neoplasms; Sindbis Virus; Topoisomerase Inhibitors | 2012 |
Gold nanocluster-conjugated amphiphilic block copolymer for tumor-targeted drug delivery.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Gold; Humans; Metal Nanoparticles; Nanocapsules; Neoplasms, Experimental; Polymers; Treatment Outcome | 2012 |
Alpha-tocopheryl polyethylene glycol succinate-emulsified poly(lactic-co-glycolic acid) nanoparticles for reversal of multidrug resistance in vitro.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Emulsions; Humans; Irinotecan; Lactic Acid; Materials Testing; Nanocapsules; Nanoparticles; Neoplasms, Experimental; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Vitamin E | 2012 |
Antibody-functionalized porous silicon nanoparticles for vectorization of hydrophobic drugs.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Diffusion; Humans; Hydrophobic and Hydrophilic Interactions; Materials Testing; Nanocapsules; Neoplasms, Experimental; Porosity; Silicon; Treatment Outcome | 2013 |
A magnetic mesoporous silica nanoparticle-based drug delivery system for photosensitive cooperative treatment of cancer with a mesopore-capping agent and mesopore-loaded drug.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; CHO Cells; Combined Modality Therapy; Cricetinae; Cricetulus; Magnetic Fields; Materials Testing; Nanocapsules; Neoplasms, Experimental; Phototherapy; Porosity; Silicon Dioxide | 2013 |
KML001 displays vascular disrupting properties and irinotecan combined antitumor activities in a murine tumor model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenites; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; Drug Synergism; Human Umbilical Vein Endothelial Cells; Humans; Irinotecan; Mice; Neoplasms, Experimental; Neovascularization, Pathologic; Sodium Compounds; Telomere | 2013 |
Combined colonic cancer treatment with vitamin D analogs and irinotecan or oxaliplatin.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Dihydroxycholecalciferols; Female; HT29 Cells; Humans; Irinotecan; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Organoplatinum Compounds; Oxaliplatin; Signal Transduction; Vitamin D; Xenograft Model Antitumor Assays | 2013 |
Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Division; Cell Survival; Colonic Neoplasms; DNA, Neoplasm; Drug Interactions; Female; Fluorouracil; Glutamates; Guanine; HT29 Cells; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Transplantation, Heterologous | 2002 |
Small-sample inference for incomplete longitudinal data with truncation and censoring in tumor xenograft models.
Topics: Algorithms; Animals; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Biometry; Camptothecin; Dacarbazine; Humans; Irinotecan; Longitudinal Studies; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Temozolomide; Xenograft Model Antitumor Assays | 2002 |
The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer.
Topics: Animals; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cell Division; Cisplatin; Colonic Neoplasms; Disease Models, Animal; Female; Humans; Membrane Glycoproteins; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Experimental; Ovarian Neoplasms; Sulfhydryl Reagents; Tetraspanin 29; Tumor Cells, Cultured; Vault Ribonucleoprotein Particles; Xenograft Model Antitumor Assays | 2002 |
Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity.
Topics: Acridines; Animals; Antigens, CD; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Cell Division; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Humans; Immunoenzyme Techniques; Isoquinolines; Membrane Glycoproteins; Mice; Mice, Nude; Mutation; Neoplasm Proteins; Neoplasms, Experimental; Ovarian Neoplasms; Tetrahydroisoquinolines; Tetraspanin 29; Tetrazolium Salts; Thiazoles; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2002 |
Preclinical activity of an i.v. formulation of rubitecan in IDD-P against human solid tumor xenografts.
Topics: Animals; Antineoplastic Agents; Camptothecin; Capsules; Drug Administration Schedule; Drug Delivery Systems; Humans; Injections, Intravenous; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Particle Size; Treatment Outcome; Tumor Cells, Cultured | 2002 |
[Anticancer effect of hydroxycampothecin on oral squamous carcinoma cell line].
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Cell Cycle; Disease Models, Animal; Female; Humans; Male; Mice; Mice, Inbred BALB C; Mouth Neoplasms; Neoplasm Transplantation; Neoplasms, Experimental; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Cell Division; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Humans; Mice; Mice, Nude; Neoplasms, Experimental; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
[Experimental studies on treatment of nasopharyngeal carcinoma with combination regimen of hydroxycamptothecin and etoposide].
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Etoposide; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Neoplasms; Neoplasm Transplantation; Neoplasms, Experimental; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |
[Inhibition of hydroxycamptothecin on laryngeal squamous carcinoma cell line].
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Disease Models, Animal; Flow Cytometry; Laryngeal Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; S Phase; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |
Experimental design and sample size determination for testing synergism in drug combination studies based on uniform measures.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Drug Synergism; Irinotecan; Mice; Models, Biological; Models, Statistical; Neoplasms, Experimental; Research Design; Sample Size; Statistics, Nonparametric; Temozolomide | 2003 |
Antiangiogenic effects of the novel camptothecin ST1481 (gimatecan) in human tumor xenografts.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms, Experimental; Transplantation, Heterologous; Tumor Cells, Cultured | 2003 |
Development and characterization of a novel liposome-based formulation of SN-38.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Chromatography, High Pressure Liquid; Drug Stability; Female; Hydrogen-Ion Concentration; Injections, Intravenous; Irinotecan; Liposomes; Male; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Neoplasms, Experimental; Time Factors; Transplantation, Heterologous | 2004 |
Biological characterization of MLN944: a potent DNA binding agent.
Topics: Animals; Antigens, Neoplasm; Camptothecin; Catalysis; Cell Cycle; Cell Line, Tumor; Cluster Analysis; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; G1 Phase; G2 Phase; Gene Expression Profiling; HCT116 Cells; Humans; Intercalating Agents; Irinotecan; Male; Mice; Mice, Nude; Mitosis; Mutation; Neoplasms, Experimental; Phenazines; Transplantation, Heterologous; Xenograft Model Antitumor Assays; Yeasts | 2004 |
DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f: potent antitumor activities in various murine tumor models.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Male; Mice; Neoplasms, Experimental | 2004 |
Novel camptothecin analogue (gimatecan)-containing liposomes prepared by the ethanol injection method.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Drug Stability; Ethanol; Humans; Liposomes; Mice; Molecular Structure; Neoplasms, Experimental; Particle Size; Stereoisomerism; Water | 2004 |
Repeated-measures models with constrained parameters for incomplete data in tumour xenograft experiments.
Topics: Algorithms; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Female; Humans; Irinotecan; Likelihood Functions; Longitudinal Studies; Mice; Mice, SCID; Models, Biological; Models, Statistical; Neoplasms, Experimental; Rhabdomyosarcoma; Temozolomide; Xenograft Model Antitumor Assays | 2005 |
Efficacy of the novel camptothecin gimatecan against orthotopic and metastatic human tumor xenograft models.
Topics: Animals; Brain; Camptothecin; Female; Humans; Melanoma; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms, Experimental; Nervous System Neoplasms; Ovarian Neoplasms; Time Factors; Xenograft Model Antitumor Assays | 2004 |
Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms, Experimental; Oligonucleotide Array Sequence Analysis; Osteonectin; Transplantation, Heterologous | 2005 |
Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; Cytosine; Disease Models, Animal; Drug Screening Assays, Antitumor; Female; Fluorouracil; Green Fluorescent Proteins; Humans; Immunotherapy; Interferons; Liposomes; Liver; Liver Neoplasms; Luminescent Proteins; Lung Neoplasms; Male; Metalloproteases; Mice; Mice, Inbred C57BL; Mice, Nude; Mice, Transgenic; Microscopy, Fluorescence; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Oligonucleotides, Antisense; Pancreatic Neoplasms; Prostatic Neoplasms; Red Fluorescent Protein | 2005 |
Chemotherapy under cachectic conditions and the possibility of cachexia-controlled chemotherapy.
Topics: Animals; Antibodies; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cachexia; Camptothecin; Cell Line, Tumor; Cyclophosphamide; Dose-Response Relationship, Drug; Interleukin-6; Irinotecan; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental; Survival Analysis; Time Factors; Treatment Outcome | 2005 |
Antivascular therapy of oral tongue squamous cell carcinoma with PTK787.
Topics: Animals; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Therapy, Combination; Follow-Up Studies; In Vitro Techniques; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Phthalazines; Prodrugs; Protein Kinase Inhibitors; Pyridines; Tongue Neoplasms; Treatment Outcome | 2005 |
Intraperitoneal versus intravenous CPT-11 given intra- and postoperatively for peritoneal carcinomatosis in a rat model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Enzyme Inhibitors; Infusions, Parenteral; Irinotecan; Male; Models, Animal; Neoplasm Transplantation; Neoplasms, Experimental; Peritoneal Neoplasms; Postoperative Period; Rats | 2006 |
Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cetuximab; Cisplatin; ErbB Receptors; Female; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms, Experimental; Xenograft Model Antitumor Assays | 2006 |
Novel polymeric prodrug with multivalent components for cancer therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Design; Female; Gonadotropin-Releasing Hormone; Humans; Molecular Structure; Neoplasm Transplantation; Neoplasms, Experimental; Ovarian Neoplasms; Polymers; Prodrugs; Rats; Xenograft Model Antitumor Assays | 2006 |
Circadian regulation of mouse topoisomerase I gene expression by glucocorticoid hormones.
Topics: Adrenalectomy; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Circadian Rhythm; DNA Topoisomerases, Type I; Gene Expression Regulation, Neoplastic; Glucocorticoids; Irinotecan; Male; Mice; Mice, Inbred ICR; Neoplasm Transplantation; Neoplasms, Experimental; Receptors, Glucocorticoid; Topoisomerase I Inhibitors | 2006 |
Effect of a novel vacuolar-H+-ATPase inhibitor on cell and tumor response to camptothecins.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Camptothecin; Enzyme Inhibitors; Female; HT29 Cells; Humans; Indoles; Irinotecan; Mice; Neoplasm Proteins; Neoplasms, Experimental; Staining and Labeling; Topotecan; Vacuolar Proton-Translocating ATPases | 2006 |
In vitro and in vivo antitumor effects of cytotoxic camptothecin-bombesin conjugates are mediated by specific interaction with cellular bombesin receptors.
Topics: Animals; Antineoplastic Agents; BALB 3T3 Cells; Bombesin; Camptothecin; Cell Proliferation; Drug Stability; Female; Humans; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Receptors, Bombesin | 2006 |
Preclinical efficacy of ST1976, a novel camptothecin analog of the 7-oxyiminomethyl series.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; DNA Cleavage; DNA Topoisomerases, Type I; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Mice; Mice, Nude; Molecular Structure; Neoplasms, Experimental | 2007 |
MEK activation suppresses CPT11-induced apoptosis in rat intestinal epithelial cells through a COX-2-dependent mechanism.
Topics: Animals; Apoptosis; Blotting, Western; Camptothecin; Cell Survival; Cyclooxygenase 2; Enzyme Activation; Enzyme Inhibitors; Epithelial Cells; Intestinal Mucosa; Intestinal Neoplasms; Irinotecan; Mitogen-Activated Protein Kinase Kinases; Neoplasms, Experimental; Rats; Signal Transduction; Tumor Cells, Cultured | 2007 |
Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors.
Topics: Animals; Antineoplastic Agents; Camptothecin; Female; Humans; Irinotecan; Liposomes; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Xenograft Model Antitumor Assays | 2008 |
Bolus oral glutamine protects rats against CPT-11-induced diarrhea and differentially activates cytoprotective mechanisms in host intestine but not tumor.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Camptothecin; Colon; Colonic Neoplasms; Cytoprotection; Diarrhea; Female; Glutamine; Irinotecan; Neoplasms, Experimental; Rats | 2008 |
DTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cations; Dogs; Drug Carriers; Humans; Irinotecan; Neoplasms, Experimental; Peptides; Prodrugs; Xenograft Model Antitumor Assays | 2008 |
Stimulation by nerve growth factor of specific protein synthesis in rat PC12 pheochromocytoma cells.
Topics: Adrenal Gland Neoplasms; Animals; Camptothecin; Clone Cells; Colchicine; Neoplasms, Experimental; Nerve Growth Factors; Nerve Tissue Proteins; Pheochromocytoma; Rats; Stimulation, Chemical; Vinblastine | 1980 |
Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Colonic Neoplasms; Female; Humans; Irinotecan; Mice; Mice, Inbred CBA; Neoplasms, Experimental; Random Allocation; Rhabdomyosarcoma; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 1995 |
CPT-11: a novel antitumor drug.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Survival; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Irinotecan; Mice; Mice, Inbred C3H; Molecular Structure; Neoplasms, Experimental; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1994 |
Comparative activity of oral and parenteral topotecan in murine tumor models: efficacy of oral topotecan.
Topics: Administration, Oral; Animals; Camptothecin; Female; Infusions, Parenteral; Mice; Neoplasms, Experimental; Topotecan | 1994 |
Inhibition of retrovirus-induced disease in mice by camptothecin.
Topics: 3T3 Cells; Acute Disease; Animals; Animals, Newborn; Camptothecin; Dose-Response Relationship, Drug; Evaluation Studies as Topic; Leukemia, Erythroblastic, Acute; Leukemia, Experimental; Lymphoma; Mice; Mice, Inbred BALB C; Moloney murine leukemia virus; Neoplasms, Experimental; Retroviridae Infections; Spleen; Spleen Focus-Forming Viruses; Virus Replication | 1993 |
Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Docetaxel; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Irinotecan; Leukemia, Experimental; Male; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Paclitaxel; Sensitivity and Specificity; Taxoids; Vincristine | 1996 |
Schedule-dependent efficacy of camptothecins in models of human cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Neoplasms, Experimental; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1996 |
Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Death; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Fluorouracil; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Survival Analysis; Topoisomerase I Inhibitors | 1997 |
Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II.
Topics: Adenocarcinoma; Aminoquinolines; Animals; Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Etoposide; Humans; Indenes; Indoles; Irinotecan; Lung Neoplasms; Male; Melanoma; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Neoplasms, Experimental; Pyridines; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1997 |
Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; DNA-Binding Proteins; Drug Resistance; Female; Genetic Therapy; I-kappa B Proteins; Irinotecan; Mice; Mice, Nude; Neoplasms, Experimental; NF-kappa B; NF-KappaB Inhibitor alpha; Recombinant Proteins; Tumor Necrosis Factor-alpha | 1999 |
Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Catalysis; Cell Division; Drug Screening Assays, Antitumor; Humans; Irinotecan; Mice; Mice, Inbred CBA; Molecular Sequence Data; Neoplasm Transplantation; Neoplasms, Experimental; Nitrobenzenes; Phenylacetates; Prodrugs; Rabbits; Tumor Cells, Cultured | 1999 |
Unique biochemical, cytotoxic, and antitumor activity of camptothecin and 4beta-amino-4'-O-demethylepipodophyllotoxin conjugates.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Disease Models, Animal; DNA; DNA Damage; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Podophyllotoxin; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2000 |
Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Delivery Systems; Drug Design; Drug Screening Assays, Antitumor; Female; Humans; Hydrolysis; Leukemia P388; Mice; Mice, Inbred ICR; Neoplasms, Experimental; Polyethylene Glycols; Prodrugs; Rats; Solvents; Tumor Cells, Cultured | 1999 |
Anti-cancer activity of 9-nitrocamptothecin liposome aerosol in mice.
Topics: Aerosols; Animals; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Female; Humans; Liposomes; Lung Neoplasms; Mice; Mice, Nude; Microscopy, Electron; Neoplasm Transplantation; Neoplasms, Experimental; Osteosarcoma; Particle Size; Transplantation, Heterologous | 2000 |
Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bacterial Infections; Camptothecin; Cell Line; Cell Survival; Female; Fluorouracil; Glucagon-Like Peptide 2; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Intestines; Irinotecan; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Peptides; Rats; Receptors, Glucagon; Survival Rate; Time Factors; Transfection; Tumor Cells, Cultured | 2001 |
Carrier and dose effects on the pharmacokinetics of T-0128, a camptothecin analogue-carboxymethyl dextran conjugate, in non-tumor- and tumor-bearing rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Carbohydrate Sequence; Cell Line; Chromatography; Dextrans; Female; Half-Life; Macrophages; Molecular Sequence Data; Neoplasms, Experimental; Prodrugs; Rats; Rats, Wistar; Tissue Distribution; Topotecan | 2001 |
Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(S)-camptothecin (Rubitecan).
Topics: Animals; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Dogs; Drug Administration Routes; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Female; Half-Life; Humans; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasms, Experimental | 2002 |
Growth inhibition of established B16-F10 lung metastases by sequential aerosol delivery of p53 gene and 9-nitrocamptothecin.
Topics: Aerosols; Animals; Antineoplastic Agents; Camptothecin; Combined Modality Therapy; Genes, p53; Genetic Therapy; Liposomes; Lung Neoplasms; Melanoma; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Survival Rate | 2002 |
GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Camptothecin; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Oligonucleotides; Oligonucleotides, Antisense; Pancreatic Neoplasms; Prostatic Neoplasms; Survival Rate; Treatment Outcome | 2002 |
Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, phar
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Oligonucleotides; Oligonucleotides, Antisense; Prostatic Neoplasms; Survival Rate; Tissue Distribution; Treatment Outcome | 2002 |
Effect of camptothecin and adriamycin on bleomycin-induced tritiated thymidine triphosphate incorporation in a rat nuclear system.
Topics: Animals; Bleomycin; Camptothecin; Carcinoma, Hepatocellular; Cell Nucleus; DNA; DNA Repair; DNA, Neoplasm; Doxorubicin; Drug Interactions; In Vitro Techniques; Liver; Liver Neoplasms; Male; Neoplasms, Experimental; Rats; Thymidine Monophosphate; Thymine Nucleotides | 1977 |
The effect of several antitumor agents on 3H-TTP incorporation in host liver and hepatoma nuclei.
Topics: Animals; Antibiotics, Antineoplastic; Bleomycin; Camptothecin; Carcinoma, Hepatocellular; Cell Nucleus; Daunorubicin; DNA; DNA, Neoplasm; DNA, Single-Stranded; Doxorubicin; In Vitro Techniques; Liver; Liver Neoplasms; Male; Mitomycins; Neoplasms, Experimental; Plicamycin; Rats; Thymidine | 1977 |
Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice.
Topics: Animals; Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Doxorubicin; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Topoisomerase II Inhibitors; Transplantation, Heterologous | 1992 |
[Effect of administration schedules on the antitumor activity of CPT-11, a camptothecin derivative].
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Fibrosarcoma; Injections, Intraperitoneal; Injections, Intravenous; Irinotecan; Leukemia L1210; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental | 1990 |
Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Doxorubicin; Drug Resistance; Irinotecan; Leukemia P388; Neoplasms, Experimental; Tumor Cells, Cultured; Vincristine | 1988 |
[Antitumor activity of new derivatives of camptothecin].
Topics: Animals; Antineoplastic Agents; Camptothecin; Doxorubicin; Irinotecan; Lethal Dose 50; Leukemia L1210; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred ICR; Neoplasms, Experimental | 1987 |
Antitumor activity of a new camptothecin derivative, SN-22, against various murine tumors.
Topics: Animals; Antineoplastic Agents; Camptothecin; Lethal Dose 50; Leukemia L1210; Mice; Mice, Inbred Strains; Neoplasms, Experimental | 1987 |
Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors.
Topics: Animals; Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Irinotecan; Mice; Mice, Inbred Strains; Neoplasms, Experimental | 1987 |
Potentially useful combinations of chemotherapy detected in mouse tumor systems.
Topics: Acetylcysteine; Animals; Antineoplastic Agents; Azauridine; Bleomycin; Camptothecin; Cyclic P-Oxides; Cyclophosphamide; Cytarabine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Ethylamines; Fluorouracil; Imidazoles; Leukemia L1210; Lung Neoplasms; Methotrexate; Mice; Neoplasms, Experimental; Oxazines; Piperazines; Procarbazine; Propane; Triazenes | 1974 |
The role of messenger RNA in tyrosine aminotransferase superinduction: effects of camptothecin on hepatoma cells in culture.
Topics: Animals; Camptothecin; Carcinoma, Hepatocellular; Cells, Cultured; Dactinomycin; Deoxyadenosines; Enzyme Induction; Hydrocortisone; Insulin; Liver; Liver Neoplasms; Neoplasms, Experimental; Protein Biosynthesis; Rats; RNA, Messenger; Time Factors; Tyrosine Transaminase | 1974 |
Action of camptothecin on mammalian cells in culture.
Topics: Animals; Camptothecin; Cell Line; Cell Survival; Cricetinae; Deoxyuridine; DNA Nucleotidyltransferases; DNA Replication; DNA, Neoplasm; Leukemia L1210; Lung; Mitosis; Neoplasms, Experimental; Phosphotransferases; RNA, Neoplasm; Thymidine Kinase; Time Factors; Tritium | 1972 |
Cell-kill kinetics of several S-phase-specific drugs.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Division; Cell Line; Cell Survival; Cricetinae; Cytarabine; DNA, Neoplasm; Formates; Hydroxyurea; Kinetics; Leukemia L1210; Lung; Mice; Neoplasms, Experimental; Pyridines; Thiosemicarbazones; Time Factors | 1973 |